- Subject is an infant aged 8 to 11 weeks at the time of first vaccination
- Subject is clinically healthy as determined by the investigator's clinical judgment
through collection of medical history and physical examination
- Subject was born at full term of pregnancy (>= 37 weeks) with a birth weight >= 2 kg
- The parent(s) or legally authorized representative of the subject provides written
consent for participation
- The parent(s) or legally authorized representative of the subject has the ability to
understand and comply with the requirements of the protocol
- The parent(s) or legally authorized representative and the subject will be available
for the duration of the study
- The parent(s) or legally authorized representative of the subject agrees to keep a
subject diary
- Subject has a history of severe allergic reactions or anaphylaxis, or has a known
sensitivity or allergy to any components of the vaccines
- Subject has had an acute or chronic infection requiring systemic therapy (antibiotic
or antiviral) or other prescribed treatment within the 2 weeks prior to the first
vaccination in this study
- Subject has a rash or dermatologic condition which may interfere with injection site
reaction rating
- Subject currently has, or has a history of, any significant cardiovascular,
respiratory, hepatic, renal, metabolic, autoimmune, rheumatic, hematological,
neurological, or neurodevelopmental disorder
- Subject has a disease, or is currently undergoing a form of treatment, or was
undergoing a form of treatment within 30 days prior to study entry, that could be
expected to influence immune response
- Subject has received any blood products or immunoglobulins within 60 days of study
entry
- Subject has received a live vaccine within 4 weeks or an inactivated or subunit
vaccine within 2 weeks of the scheduled first vaccination
- Subject has previously been vaccinated against meningococcal C disease
- Subject has a known or suspected immune dysfunction
- Subject has a functional or surgical asplenia (e.g. due to a pathologic
hemoglobinopathy, leukemia, lymphoma, etc.)
- Subject was administered an investigational drug within six weeks prior to study entry
or is concurrently participating in a clinical study that includes the administration
of an investigational product
- Subject or his/her parent(s) / legally authorized representative are in a dependent
relationship with the study investigator or with a study team member; dependent
relationships include close relatives (i.e. children, partner/spouse, siblings) as
well as employees of the investigator or site conducting the study